Tag: 2026

Texas Hemp Regulatory Update: Emergency Rules Extended

Written by Jay Maguire on February 10, 2026. Posted in CBD News & Business.

A Narrow Window, Not a Free Pass

The Texas Department of State Health Services has formally extended the emergency rules governing consumable hemp products through March 30, 2026, as reflected in the February 6, 2026 Texas Register. These rules—first adopted in October 2025—remain in effect without substantive change. No new restrictions were added. No permanent rules were finalized.

This matters because the state had a choice. It could have locked in final rules and forced the issue legally and politically. Instead, it chose to extend temporary authority. That is not an accident. It is a pause.

The emergency extension keeps the current guardrails in place, including age-based sales restrictions, while avoiding a permanent regulatory position that would invite immediate legal challenge and legislative backlash. In plain terms, the state is holding its ground without planting a flag.

What this action does not do is just as important. It does not settle the future of hemp regulation in Texas. It does not expand enforcement authority. It does not criminalize new conduct. It does not resolve disputes over testing standards, product categories, or agency overreach. It simply preserves the status quo—briefly.

That brief preservation is the opportunity.

Emergency extensions are breathing room, not absolution. They create time for the industry to show whether it can operate credibly under scrutiny or whether the state will feel justified in tightening the vise. Every regulator and elected official understands this distinction, even if they do not say it out loud.

This is the moment when voluntary compliance stops being a philosophical preference and becomes a strategic necessity.

Certified training programs, documented age-gating, truth in labeling, truth in testing, verified brands, and clean supply chains are no longer just internal best practices. They are evidence. They are proof points that can be shown to the Governor’s Office and to legislators who are still persuadable. They answer the only question that really matters right now: Can this industry govern itself responsibly if allowed to continue operating?

Everything done during this window will be noticed. Good conduct compounds. Bad conduct will be amplified and used as justification for permanent restrictions that will be far harder to undo. There is no private behavior in this environment. There is only behavior that strengthens the case for rational regulation, or behavior that hands opponents exactly what they want.

Texas has not slammed the door. It has left it cracked open.

Whether that crack becomes a stable regulatory framework or snaps shut into overreach depends on what the industry does next. This window is real. It is short. And it should not be squandered.

The Lawsuit That Changes the Kratom Debate

Written by Jay Maguire on February 10, 2026. Posted in Texas Legal & Regulatory News.

For years, kratom existed in a regulatory gray zone—debated, periodically regulated, but rarely confronted through full-scale state enforcement. That equilibrium broke on February 6, 2026, when the Texas Attorney General filed suit in Ellis County seeking an ex parte temporary restraining order, temporary and permanent injunctions, and civil penalties against two smoke shop operators accused of selling illegal kratom products .

The State’s opening claim is blunt and unambiguous:

“Kratom is addictive and deadly.”

According to the petition, Texas health officials and lawmakers are no longer dealing with traditional botanical kratom, but with what the filing describes as “potent and dangerous concentrations of synthetic alkaloids” that bear little resemblance to the plant historically consumed in Southeast Asia .

The lawsuit alleges that products sold at Smokey’s Paradise retail locations contained 7-hydroxymitragynine (7-OH) at levels that “significantly exceed[] the 2% statutory limit” imposed by the Texas Kratom Consumer Health and Safety Protection Act. In some cases, laboratory testing allegedly found 7-OH making up “96% of the tablet”—a concentration the State characterizes as “forty-nine times the legal limit” .

Even more consequential is the State’s allegation that several products contained mitragynine pseudoindoxyl, a compound the petition states “is not a natural alkaloid present in botanical kratom leaves” and “must be synthetically produced” . Under Texas law, the presence of synthetic alkaloids alone is sufficient to render a kratom product illegal.

The petition identifies specific branded products allegedly purchased by investigators and sent for independent laboratory testing, including Dozo Perks 7-OH tablets, 7OHMZ 7-OH tablets, 7Tabz 7-OH tablets, 7O’Heaven 7-OH liquid shots, and Tahi Mahji tablets .

The State does not frame these allegations as technical violations. Instead, it situates them squarely within an opioid-risk narrative. The filing describes 7-OH as “a potent mu-opioid receptor agonist with pharmacological properties similar to morphine and fentanyl” and warns that products containing concentrated 7-OH can cause “respiratory depression, physical dependence, and withdrawal symptoms characteristic of classical opioids” .

From a legal standpoint, the enforcement posture is as aggressive as the rhetoric. The Attorney General argues that when a statute is violated, courts need not weigh competing harms. Citing Texas precedent, the petition states that “the status quo can never be the continuing violation of a law,” and that the State’s “inability to enforce its duly enacted laws clearly inflicts irreparable harm” .

That framing matters. It allows the State to seek immediate injunctive relief without the delays typically associated with protracted litigation. In practical terms, it means retailers can be ordered to stop selling an entire product category before any final ruling on the merits.

For legislators, the lawsuit provides something equally valuable: a ready-made factual record. The petition assembles poison-center data, FDA warnings, DEA classifications, and laboratory findings into a narrative that recasts kratom not as an herbal supplement with compliance problems, but as an emerging synthetic opioid threat. Once that framing is adopted, legislative outcomes tend to follow.

The implications extend beyond kratom alone. Regulators do not evaluate retail compliance in isolation. Stores alleged to sell illegal synthetic products are more likely to be viewed as systemic risks, a perception that can spill over into inspections, licensing decisions, and enforcement priorities affecting other product categories, including hemp-derived THC.

The Ellis County case is therefore best understood not as an isolated dispute, but as a template. It shows how kratom enforcement is likely to proceed and how legislative debates will be shaped going forward. The State has moved past warnings and into injunctions, past regulation and toward elimination.

For an industry accustomed to regulatory ambiguity, the message is suddenly precise. The kratom debate has entered its endgame, and the first decisive move has already been filed in court.